Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals

BRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's epinephrine injection USP, 1 mg/mL (1 mL), in single-dose vials and 1 mg/mL (30 mL) multi-dose vials. This medicine is a critical therapy utilized by hospitals, emergency departments and other acute care facilities for patient care.

GlobeNewsWire • Dec 9, 2025

Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson's Disease

BRIDGEWATER, N.J., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced new positive interim results from its ongoing Phase 4 ELEVATE-PD study, presented at the Parkinson's Study Group (PSG) Annual Meeting.

GlobeNewsWire • Dec 5, 2025

Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol

BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's albuterol sulfate inhalation aerosol (90 mcg per actuation).

GlobeNewsWire • Dec 2, 2025

Amneal to Participate in Upcoming Investor Conferences

BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, and Tasos Konidaris, Chief Financial Officer, will participate in following upcoming investor conferences:

GlobeNewsWire • Dec 2, 2025

Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%

Approval underscores Amneal's advanced sterile manufacturing capabilities and expansion within complex ophthalmic therapies; Launch expected in Q1 2026  BRIDGEWATER, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved the Company's cyclosporine ophthalmic emulsion 0.05%, a sterile, preservative-free formulation supplied in single-use vials.

GlobeNewsWire • Dec 1, 2025

Is Amneal Stock a Buy After Investment Firm Westshore Wealth Bought Over 1 Million Shares?

Westshore Wealth initiated 1,381,910 shares in Amneal Pharmaceuticals, a position value increase of $13.83 million. The transaction accounted for 4.73% of Westshore's 13F reportable assets under management.

The Motley Fool • Nov 28, 2025

ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick?

ANI Pharmaceuticals' rare-disease momentum, led by surging Cortrophin Gel sales, sets up a stronger growth profile than its diversified rival.

Zacks Investment Research • Nov 28, 2025

Amneal EVP Sells $1.6 Million in Shares as Stock Trades Near Multi-Year Highs

The option-exercise sale represented a notable amount of Shah's overall holdings. Nevertheless, the executive's remaining stake—about 146,000 shares—still represents meaningful exposure.

The Motley Fool • Nov 21, 2025

Amneal Receives U.S. FDA Approval for Iohexol Injection

BRIDGEWATER, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved the Company's iohexol injection (300 mg Iodine/mL), the first generic version of GE Healthcare's Omnipaque® (iohexol) injection.

GlobeNewsWire • Nov 13, 2025

Amneal Pharmaceuticals, Inc. (AMRX) Q3 2025 Earnings Call Transcript

Amneal Pharmaceuticals, Inc. ( AMRX ) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Anthony DiMeo - Head of Investor Relations Chirag Patel - Co-Founder, Co-CEO, President & Director Chintu Patel - Co-Founder, Co-CEO & Director Anastasios Konidaris - Executive VP & CFO Conference Call Participants Matthew Dellatorre - Goldman Sachs Group, Inc., Research Division Leszek Sulewski - Truist Securities, Inc., Research Division Ekaterina Knyazkova - JPMorgan Chase & Co, Research Division David Amsellem - Piper Sandler & Co., Research Division Presentation Operator Good morning and welcome to the Amneal Pharmaceuticals Third Quarter 2025 Earnings Call. I will now turn the call over to Amneal's Head of Investor Relations, Tony DiMeo.

Seeking Alpha • Oct 30, 2025